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Abstract
Carcinogenesis and neoplastic progression are mediated by the accumulation of somatic
mutations. Here we report that the local density of somatic mutations in cancer genomes is highly
reduced specifically in accessible regulatory DNA defined by DNase I hypersensitive sites. This
reduction is independent of any known factors influencing somatic mutation density and is
observed in diverse cancer types, suggesting a general mechanism. By analyzing individual cancer
genomes1, we show that the reduced local mutation density within regulatory DNA is linked to
intact global genome repair machinery, with nearly complete abrogation of the hypomutation
phenomenon in individual cancers that possess mutations in multiple nucleotide excision repair
components. Together, our results connect chromatin structure, gene regulation and cancer-
associated somatic mutation.
Somatic mutations are a major contributor to cancer development and progression. In cancer
cells, the density of somatic mutations is highly heterogeneous along the genome2,3.
However, mechanisms governing the genomic distribution of somatic mutations are poorly
understood. Recently, cancer genomics efforts have accumulated data on somatic mutations
in tumors4, revealing that the relative density of somatic mutations in protein coding genes
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t(including both introns and exons) is lower than the genome average5. This effect has been
posited to result from transcription-coupled DNA repair (TCR)2,3, which is mediated by the
recruitment of the nucleotide excision repair (NER) system by Pol II RNA polymerase
stalled at pre-mutation lesions6,7. The existence of such an effect raises the question whether
other similarly specialized repair mechanisms operate on other functionally important
genomic regions.
Regulatory DNA (promoters, enhancers, insulators, etc.) active within a given cell type is
characterized by hypersensitivity to DNase I8, resulting in DNase I hypersensitive sites
(DHSs) that quantitatively reflect regulatory factor binding in place of canonical
nucleosomes9,10. It has long been posited that the accessibility of DNA within regulatory
regions may render such regions more susceptible to DNA damage-induced mutation11.
Evolutionary rates of sequence divergence within DHS found in cancer genomes and
primitive cells are higher than normal differentiated cells8, and density of somatic variants
detected in a cancer sample that underwent cell culture was shown to be reduced in DHS
more than density of common SNPs12. However, particularly in view of the variability in
somatic mutation rates along cancer genomes, a quantitative understanding of mutation
within regulatory DNA, together with insight into the underlying biological mechanisms,
has not been explored.
Results
Reduced local density of somatic mutations in DHSs
To examine mutation frequencies in regulatory DNA, we mapped DHSs genome-wide in 12
cancer cell lines, as well as normal cellular counterparts of major malignancies (see
Methods). We then analyzed whole-genome sequencing data from 34 tumor/normal pairs
from seven distinct datasets: small-cell lung cancer3, melanoma2, 23 multiple myeloma5
(MM) samples, and 9 colon cancers13. We used published mutation data for small-cell lung
cancer3 and melanoma cell lines2 (http://icgc.org) and re-analyzed primary tumor data on
multiple myeloma and colon cancer using MuTect 14 (http://www.broadinstitute.org/
cancer/cga/mutect). These 34 cancer genomes contained 364,226 somatic point mutations in
about 2.6 Gbp of sequence that could be uniquely mapped in the DHSs assay, i.e. density of
0.000139 per base-pair (bp).
We observed a substantial reduction in the frequency of somatic nucleotide substitutions in
DHSs compared to the genome average (Fig. 1 and Supplementary Fig. 1). This reduction is
highly significant and consistent across all tumors (P <10-36, chi-square test). The reduction
was most prominent in the core TF binding regions of DHSs marked by the maxima of
DNase I cleavage intensity (Fig. 1).
We next confirmed that the reduction of frequency of somatic mutations in DHSs was not
the result of confounding factors influencing local variation in cancer mutation density, nor
the result of sequencing and mapping biases15. Confounding factors may include differences
between intergenic regions and genes (including both exons and introns), distance from
transcription start sites2 (Supplementary Fig. 2), time of DNA replication during the S-
phase16, distances to telomeres and centromeres, and local G+C content15. Relative density
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tof somatic mutations also depends on sequence context, especially flanking nucleotides, and
different tumors exhibit different context dependencies2,3,13 (Supplementary Fig. 3). The
relative density of mutations expected from the sequence context is higher in DHSs,
magnifying our observation (P <5*10-181).
We observed significant relative reduction of somatic mutations in DHSs located in both
intronic and intergenic regions, and in DHSs proximal (<1 kb) to transcription start sites
versus more distal DHSs (Supplementary Fig. 4). More notably, the reduction was evident in
comparison to immediately flanking 1kb regions (P <2.2*10-16, chi-square test in lung, MM
and colon; P=7.21*10-13 in melanoma). As such, the observed reduction in the density of
somatic mutations cannot be explained by a regional factor acting over long ranges17 such as
transcription or DNA replication timing.
To rule out biases related to sequencing and mapping, for two of the cancer types (colon13
and MM5) with available raw sequencing data we repeated the analysis restricting it to
nucleotide positions with above 80% detection power based on sequencing coverage. This
analysis confirmed that the density of somatic sequence alterations is significantly reduced
in DHSs compared to 1kb flanking sequences.
To account collectively for all of the above potential confounding factors, we applied
Poisson regression model18. DHSs remained a significant and substantial contributor to the
local somatic mutation frequency on top of other factors, including DNA replication
timing19, distance from transcription start sites, distance from the DHS itself, CpG islands
status, G+C content, and region type (exonic, intergenic, intronic) (Supplementary Tables 1
and 2). Because our regression analysis included neighboring windows, short-range regional
dependencies could potentially inflate statistical significance. We repeated the analysis using
a small subset (20%) of spatially separated windows and confirmed that DHSs remain a
highly significant contributor even if only 20% of data are used (Supplementary Tables 1
and 2).
Notably, the effect of chromatin accessibility is monotonic and continuous and thus does not
depend on the specific thresholds used to define DHSs (Supplementary Fig. 5). Finally,
DHSs mapped in potential cells or tissues of origin (e.g., lung tissue for lung carcinoma, etc;
see Methods) substantially contribute to the regression model that already includes pooled
DHSs from multiple cell types. This demonstrates that cell-selective chromatin architecture
and not simply genomic location is the driving feature.
The observed reduction in the frequency of somatic sequence changes within DHSs might
be explained by either reduced occurrence of somatic mutation or by the action of purifying
selection. At present, purifying selection in cancers has not been carefully studied, so we
lack information that would support or contradict the action of purifying selection. In
general, population genetics and comparative genomics studies in a variety of organisms
suggest that purifying selection is usually stronger in coding regions than in regulatory
regions20,21. To investigate the possible action of purifying selection, we compared relative
mutation densities in regulatory and protein-coding regions. The average reduction (across
cancers) in frequency of somatic mutations in coding sequences relative to flanking
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tsequences is smaller than analogous reduction in DHSs (Supplementary Fig. 6).
Furthermore, the observed reduction of mutation frequency in exons may not necessarily
represent the action of purifying selection. The frequency of missense mutations is not lower
(and is even apparently higher) than frequency of synonymous changes (Supplementary Fig.
6). Thus, although it is possible that cancers may differ from evolving populations and
cannot rule out the action of purifying selection in regulatory regions, we suggest that
mutation attenuation plays a more important role.
Association with nucleotide excision repair
Relative mutation density depends on replication fidelity, levels of DNA damage or
efficiency of DNA repair. The fact that the observed relative reduction of mutation density
was highly limited to DHSs, makes it difficult to explain it by an increase in global
replication fidelity. It is also unlikely that more accessible DNA at DHSs would be less
prone to damage than less accessible DNA elsewhere. In fact, mutation frequencies
observed in model organisms are reduced by positioned nucleosomes22,23, while the effects
of nucleosome positioning on somatic mutations in cancer are relatively small and differ in
directions between various cancer types15.
Chromatin accessibility plays a major role in targeting nuclear proteins to regulatory DNA,
and may provide a mechanism for preferential access by the repair machinery. Preferential
activity of DNA repair proteins in accessible regulatory DNA may thus offer an explanation
for the observed effect, analogous to the action of transcription-coupled repair in protein
coding genes. We hypothesized specifically that potentiation of nucleotide excision repair
(NER) and base excision repair (BER) by chromatin accessibility could be responsible for
the observed relative reduction of mutation density at DHSs. The level of oxidative stress
and the subsequent accumulation of lesions targeted by BER24 is higher in malignant vs.
normal cells25. BER is an evolutionary conserved DNA repair pathway, which starts from
the recognition and excision of various base lesions by specific DNA glycosylases, followed
by the processing of the resulting AP sites and then DNA repair synthesis and ligation.
Direct access of glycosylases to DNA lesions is pivotal for this repair process26. Not
surprisingly, therefore, BER complexes preferentially assemble in non-nucleosomal regions
in response to oxidative stress27, which naturally targets them to DHSs.
The NER pathway consists of two converging branches: global genome repair and
transcription-coupled repair (TCR). DNA damage is first recognized by the XPC complex,
DNA duplex is opened by XPD and XPB helicases, followed by the incision of the damaged
strand XPF-ERCC1 and XPG nucleases, then gap filling by the replication polymerases and,
finally DNA ligation28. A priori, NER machinery shall be able to correct damaged DNA
regardless of its chromatin state. A fully assembled NER complex, however, has a footprint
of ~100 bps in DNA, which is significantly longer than the length of an internucleosomal
linker. As a result, chromatin structure inhibits functional NER complex assembly and
function29-31. In case of TCR, this problem is circumvented by the fact that DNA damage is
first sensed by the RNA polymerase followed by NER recruitment to an already unraveled
chromatin requires by the CSB and CSA proteins (reviewed in ref. 6). This is not the case
for global genome repair, and the problem is additionally acerbated by the fact that the
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tdamage sensor, the XPC complex, cannot bind to DNA adducts embedded in
nucleosomes32. Thus, both lesion recognition and repair complex assembly may be
potentiated in accessible chromatin29,33. The fact that roughly half of DHSs lie in intergenic
regions suggests GGR as the more likely candidate. Notably, nucleosomal chromatin
appears to inhibit global genome repair function29-31. Moreover, the XPC complex involved
in damage recognition is inhibited from binding to lesions in nucleosomal DNA32. Thus,
both lesion recognition and repair complex assembly may be potentiated in accessible
chromatin29,33.
Failure of NER predisposes to cancer. This is best illustrated by the extreme frequency of
cancers caused by exposure to sunlight in Xeroderma pigmentosum (XP) patients, evidently
due to their inability to repair UV photoproducts in DNA. Mutations in NER are commonly
detected in melanomas. Similarly to XP, most somatic mutations observed in melanoma
cells are C:G→T:A transitions caused by ultraviolet (UV)34 damage, which are primarily
repaired by NER.
BER and NER are high fidelity pathways as suggested by studies showing that deactivation
of these pathways leads to increased chance of mutation from cryptic lesions or exogenous
DNA damage34-37. As was shown recently, NER defects lead to increase in density of
C:G→T:A mutations under chronic low-dose UV radiation, conditions specifically relevant
to melanoma38.
We, therefore, reasoned that the relative reduction of mutation density in DHSs in individual
melanoma genomes should parallel the integrity of NER pathway components. To test this,
we analyzed 29 individual melanoma genomes sequenced at high coverage1. Figure 2 and
Supplementary Table 3 show the continuous dependence of C:G→T:A mutation densities on
chromatin accessibility in melanocytes in both intergenic regions, introns and exons. We
note that the observed effect is inconsistent with the recently discovered action of APOBEC
proteins39-41. First, APOBEC acts on single strand DNA and it is unlikely that inaccessible
and untranscribed DNA would more readily adopt single strand conformation than DNA in
DHSs and transcribed regions. Second, action of APOBEC would preferentially increase
rates of C→T transitions and C→G transversions within TCA/TCT motif. Our observation
is not confined to this motif, and we do not detect a parallel effect for C→G changes
(Supplementary Fig. 7). Quantitatively, dependence of mutation density within TCA/TCT
motif on number of DNase I cleavages is slightly lower (rather than higher) than the
dependence of mutations within TCG/TCC motif (p-value for the interaction term in the
regression analysis in Supplementary Figure 7 is 2.11×10-5). This is inconsistent with the
hypothesis that APOBEC action induces the observed dependency on chromatin
accessibility.
This effect was far more pronounced in melanocyte chromatin vs. that of other cell.
Furthermore, the signature of TCR activity is also observed by the higher density of C→T
over G→A in the non-template strand2 of exons and introns (Supplementary Fig. 8). This
demonstrates that NER provide genes a multi layer protection against UV-light damage due
to activity of TCR and the accessibility of chromatin to global genome repair.
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tOverall, 9 out of 29 melanoma genomes harbored non-synonymous mutations in NER
genes. Notably, four melanoma genomes with the lowest levels of mutation reduction at
DHSs all harbor mutations in NER genes42-44 (P < 0.0237, Wilcoxon-Mann-Whitney test;
Fig. 3). In three of these samples, mutation frequencies in DHSs return close to the genomic
baseline. The presence of genomes with mutations in NER genes and reduced mutation
frequencies in DHSs is not surprising because NER mutations may appear late in cancer
development and some of the missense mutations may be functionally benign. This result
implicates NER into observed reduction of mutation frequency in DHSs. It also provides an
additional argument against selection explanation because purifying selection would not be
expected to differentially impact melanoma samples.
Eight out of the nine samples with mutations in NER pathway genes harbored mutations in
major components of the NER machinery (XPG/ERCC5, XPF/ERCC4 and LIG1). These
lesions would be expected to compromise both NER and TCR, and therefore should affect
mutation density in both DHSs and transcribed regions. Intriguingly, one of these samples
also harbored a mutation in CETN2, which recognizes DNA distortions and therefore
preferentially impacts GGR function over TCR45. In agreement with this reasoning, three
genomes carrying mutations in core subunits had markedly reduced or negligible reduction
of mutation density in transcribed regions compatible with defective TCR (Fig. 4).
Concordantly, in the genome carrying a mutation in the CETN2 gene, strong suppression of
mutations in transcribed regions remained, implying that TCR function was not significantly
compromised.
Discussion
Taken together, our results suggest that relative density of somatic mutations in cancer
genomes is substantially suppressed in regulatory DNA, and that mutation frequency closely
tracks chromatin accessibility. The hypomutational effect is highly localized and is
statistically associated with intact global genome repair. The analysis of individual
melanoma samples suggests that relationship between relative mutation density and
chromatin accessibility may be mediated by DNA repair. Our analysis could not completely
rule out alternative explanations such as selection for regulatory function or increased C→T
deamination through enzymatic activities getting abnormal access to DNA. However, these
alternatives would require to invoke yet unknown mechanism46 to explain association with
NER in melanoma.
Our results link fine-scale chromatin accessibility with the cancer mutation accumulation.
Given the growing interest in the role of regulatory sequences in cancer progression47, these
results will help providing a necessary baseline for cancer genomics projects targeting non-
coding regions, similarly to computational approaches used in the analysis of protein-coding
genes48.
With the increasing amount of whole genome sequencing data, our approach can also be
formalized and extended to associate mutational patterns with specific pathways, including
DNA repair, DNA replication and chromatin remodeling. Mutational patterns can be treated
as traits of individual tumor samples. With the large number of tumor samples available,
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controlling mutagenesis, potentially identifying important players shaping somatic
mutational landscapes.
Online Methods
DNaseI hypersensitivity mapping
DNaseI mapping was conducted on cultured cancer cell lines, primary ex vivo
hematopoietic cells, cultured primary cells, and isolated fetal tissues using appropriate nuclei
isolation protocols (below), followed by a standard processing pipeline. Data from lines
A549, HepG2, LNCap, CACO2, PANC1, CLL, K562, CMK, NB4, and MCF7 derive from
Reference 8. Generation of new data from M059J (Glioblastoma), RPMI_7951 (melanoma),
CD19 (B-cell), CD20 (B-cell), melanocytes, fetal lung and fetal intestine are described
below.
Isolation of nuclei from cultured cancer cell lines
Cells were cultured in accordance with the detailed protocols provided at http://
www.uwencode.org/protocols. To prepare nuclei, freshly grown cells were centrifuged at
500g for 5 minutes (4°C) in an Eppendorf Centrifuge 5810R, and washed in cold PBS
(Cellgro/Mediatech Inc.). Cell pellets were resuspended in Buffer A (15 mM Tris-Cl pH 8.0,
15 mM NaCl, 60 mM KCl, 1 mM EDTA (Ambion/Life Technologies Corp) pH 8.0, 0.5 mM
EGTA (Boston BioProducts) pH 8.0, 0.5 mM spermidine (MP Biomedicals, LLC) and 0.15
mM spermine (MP Biomedicals, LLC) to a final concentration of 2 × 106 cells/mL. Nuclei
were obtained by dropwise addition of an equal volume of Buffer A containing 0.04%
IGEPAL CA-630 (Sigma-Aldrich) to the cells, followed by incubation on ice for 10 min.
Nuclei were centrifuged at 1,000g for 5 min and then resuspended and washed with 25 mL
of cold Buffer A. Nuclei were resuspended in 2 mL of Buffer A at a final concentration of 1
× 107 nuclei/mL.
Isolation of nuclei from hematopoietic cells
CD19+ and CD20+ cells (separately) were isolated by immunomagnetic separation by the
Large Scale Cell Processing Facility at the Fred Hutchinson Cancer Research Center from
normal volunteer donors under an IRB-approved protocol. Cells were pelleted by
centrifugation for 5 minutes at 500g at 4 °C. Cells were washed in ice-cold PBS, then
resuspended to 5 million cells per mL in Buffer A. An equal volume of ice-cold 2X IGEPAL
CA-630 solution (ranging from 0.02%-0.06%) was added and the tube was incubated for 5 -
6 minutes on ice to lyse the cells. Nuclei were pelleted by centrifugation for 5 minutes at
500g at 4 °C, resuspended in Buffer A and counted with a hemocytometer.
Isolation of nuclei from fetal tissues
Fetal lung and intestine tissues were obtained from morphologically normal fetuses by the
Birth Defects Research Laboratory in the Dept. of Pediatrics at University of Washington,
collected under an IRB-approved protocol. Tissue was minced, resuspended in cold 250 mM
sucrose, 1 mM MgCl2, 10 mM Tris-Cl pH 7.5, with added EDTA Protease Inhibitor
Cocktail (Roche Applied Science Corp.). Resuspended tissue from fetal brain, fetal lung,
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tfetal kidney, and fetal adrenal was dissociated by slowly homogenizing with a Dounce
homogenizer. Resuspended tissue from fetal heart or fetal intestine was dissociated in a
gentleMACS Dissociator (Miltenyi Biotech Inc.). Following dissociation, all fetal tissues
were filtered through a 100 uM filter, and nuclei pelleted by centrifugation 600g for 10
minutes. Pelleted nuclei were washed with Buffer A, resuspended in Buffer A and counted
in a hemocytometer.
DNaseI mapping from isolated nuclei
Briefly, DNaseI digestion was performed as described in Reference 8, with minor
modifications. Isolated nuclei (2 × 106) from suspension cells or dissociated tissue were
washed with 15 mM Tris-Cl pH 8.0, 15 mM NaCl, 60 mM KCl, 1 mM EDTA pH 8.0, 0.5
mM EGTA pH 8.0, 0.5 mM spermidine and 0.15 mM spermine then subjected to DNaseI
digestion for 3 min at 37 °C in 13.5 mM Tris-HCl pH 8.0, 87 mM NaCl, 54 mM KCl, 6 mM
CaCl2, 0.9 mM EDTA, 0.45 mM EGTA, 0.45 mM Spermidine. Digestion was stopped by
addition of 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 0.1% SDS, 100 mM EDTA pH 8.0, 1
mM spermidine, 0.3 mM spermine. A range of DNaseI (Sigma-Aldrich), 10–80 U/mL)
concentrations was used for each preparation of nuclei and the sample giving the optimum
difference between DNaseI treated and untreated was used for sequencing library
construction. DNaseI double-hit fragments were collected by ultra-centrifugation and gel-
purified. Adaptors were ligated to the ends of purified fragments, and the resulting libraries
sequenced on an Illumina Genome Analyzer IIx according to a standard protocol.Processing
of DNaseI-seq data. 36-base reads with up to two mismatches were mapped to the human
genome (GRCh37/hg19) using the sequence aligner BOWTIE. DHSs were identified using
the Hotspot algorithm (8) at a false discovery rate (FDR) threshold of 5%. Genomic feature
overlaps and distance calculations were performed using the BEDOPS suite of software
tools available at http://code.google.com/p/bedops/.
Data availability
All DNaseI data used in this study have been released to the ENCODE Project repository or
to the Roadmap Epigenomics Mapping Consortium data coordination center. These data
have been deposited in GEO under accession numbers GSE29692 and GSE18927. Data are
also available for download through www.uwencode.org/data and through the data links at
www.epigenomebrowser.org.
Cancer datasets
We restricted our study to cancer genomes sequenced by Sanger Institute and by Broad
Institute Whole genomes of COLO-829 and NCI-H209 cell lines that have been sequenced
by Sanger Institute2,3. COLO-829 cell line has been derived from metastatic tissue. NCI-
H209, an immortal cell line of a small cell lung cancer derived from a bone marrow
metastasis. Nine colon cancer genome13, 23 multiple myelomas5 and 29 melanoma genomes
have been sequenced by Broad Institute. For the 4 Broad institute datasets we identified sites
in the genome were we have over 80% power to detect mutations (this defined by at least 14
reads the covered his position in the tumor sample and 8 reads that cover this position in
normal). About 81% of the bases in colon and MM genomes are sufficiently covered and
about 86% of the melanoma genomes are sufficiently covered.
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gene and exon coordinates were retrieved for hg19 from UCSC genome browser. For the
flank analysis we took 1000 bps windows around the DHSs, since some of flank regions
overlapped with DHSs we removed the DHS defined sites from the original set of flanks.
Density of mutations
We calculated the number of mutations per bps that can be mapped uniquely by the DHS
essays.
Poisson regression
In order to test whether DHS regions have an additional impact on rates on top of other
cofounding factors we used multivariate Poisson regression18. We divided the genomes into
non-overlapping 400 bp windows. Every bin was classified as intergenic, intronic and
exonic regions. The windows were also classified as DHS regions when overlap at least
80bp of any DHSs. For each window we calculated the following quantities: GC content,
CpG content, distance from the nearest transcription start site, distance from nearest CpG
islands, distance from nearest DHSs, and mutation counts and coverage (i.e. the number of
bases which we have 80% power to detect mutation) for Colon, multiple myeloma, and
similarly the number of GC bases in a window that are covered in Broad Institute melanoma
samples. Then using glm function in R we calculated the estimated rates18. We repeated the
analysis for spatially separated windows comprising 20% of the data to ensure that possible
short-range interdependence between neighboring windows does not artificially inflate
statistical significance.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Relative density of somatic mutations is reduced in DHSs of all analyzed cancer genomes
(lung3, melanoma2, colon13, multiple myeloma5). Mutation density per (uniquely mappable)
bp is shown for 1) DHS maxima defined as plus or minus 75 bp around the peak of DNase I
hypersensitivity (marked as DHS peaks), 2) DHSs, 3) 1000 bp flanking regions and 4)
overall genome. Mutation density in DHSs is substantially lower in comparison with
immediate flanking regions and genome average. The effect is stronger for DHS maxima
compared to overall DHSs.
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Density of somatic C:G→T:A transition mutations in melanoma samples strongly depends
chromatin accessibility in a monotonic and continuous fashion. Density of C:G→T:A
transitions per C:G base-pair in 400bp genomic intervals is shown as function of chromatin
accessibility in melanocytes measured by the density DNase I cleavages. The dependence is
presented separately for introns and intergenic regions, and is equally present in both.
Mutation densities are parametrically fitted to a spline function using a Generalized Additive
Model Poisson regression model18.
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Normalization of DHS hypomutation in melanoma genomes with mutated nucleotide
excision repair pathway genes. Relative mutation density in DHSs of melanoma genomes is
shown for samples with an intact NER system (blue) and samples with non-synonymous
mutations in NER pathway genes (red). Non-synonymous changes in NER pathway genes
significantly track relative mutation reduction in DHSs (P < 0.0237, Wilcoxon-Mann-
Whitney test).
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tFigure 4.
Reduction of mutation density in DHSs and in transcribed regions. Shown for individual
melanoma samples (scatter plot) are non-synonymous mutations in genes involved in NER
(marked by shape and color corresponding to each gene). Roles of these genes within NER
pathway are shown by the diagram on the right. XPG, XPF and LIG1 are core repair
components; CETN2 and DDB2 are specific to GGR and are involved in lesion recognition.
CSB is specific to TCR and is involved in recruiting NER to the stalled Pol II RNA
polymerase. Samples with low level (or no) reduction of somatic mutations in DHSs and
carrying non-synonymous changes in genes of core NER components also show low level
(or no) reduction of mutation frequency in transcribed regions, suggesting that core NER
genes are responsible for both effects.
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